A method is described for measuring amiodarone in human plasma and tablets using a LiChrosorb RP-18 column, a mobile phase methanol-acetonitrile-phosphate buffer pH 2.6 (80:15:5, v/v) and UV detection at 254 nm. Another antiarrhythmic drug - aprindine was used as an internal standard (i.s.).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk Estimation of Severe Primary Graft Dysfunction in Heart Transplant Recipients Using a Smartphone.
Rev Cardiovasc Med
January 2025
Cardiac Surgery, Lausanne University Hospital CHUV Lausanne, 1011 Lausanne, Switzerland.
Background: Currently, there are no standardized guidelines for graft allocation in heart transplants (HTxs), particularly when considering organs from marginal donors and donors after cardiocirculatory arrest. This complexity highlights the need for an effective risk analysis tool for primary graft dysfunction (PGD), a severe complication in HTx. Existing score systems for predicting PGD lack superior predictive capability and are often too complex for routine clinical use.
View Article and Find Full Text PDFA retrospective 'target trial emulation' comparing amiodarone and lidocaine for adult out-of-hospital cardiac arrest resuscitation.
Resuscitation
January 2025
West Virginia University School of Medicine, Department of Emergency Medicine, Division of Prehospital Medicine.
Objective: The administration of amiodarone or lidocaine is recommended during the resuscitation of out-of-hospital cardiac arrest (OHCA) patients presenting with defibrillation-refractory or recurrent ventricular fibrillation or ventricular tachycardia. Our objective was to use 'target trial emulation' methodology to compare the outcomes of patients who received amiodarone or lidocaine during resuscitation.
Methods: Adult, non-traumatic OHCA patients in the ESO Data Collaborative 2018-2023 datasets who experienced OHCA prior to EMS arrival, presented with a shockable rhythm, and received amiodarone or lidocaine during resuscitation were evaluated for inclusion.
Dronedarone a comprehensive drug profile.
Profiles Drug Subst Excip Relat Methodol
January 2025
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.
This comprehensive drug profile provides a detailed exploration of Dronedarone, an antiarrhythmic medication used for regulating irregular heartbeats. This chapter covers various aspects of Dronedarone, including its nomenclature, formulae, physical characteristics, methods of preparation, and analytical methods. The nomenclature section presents the IUPAC and nonproprietary names of Dronedarone, along with its proprietary names.
View Article and Find Full Text PDFThe Safety Profile of Amiodarone Among Older Adults (age ≥ 75 years): A Pharmacovigilance Study from the FDA Data.
Am J Med
January 2025
The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Sheba Medical Center, Ramat-Gan, Israel; Division of Geriatric Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address:
Background: Amiodarone is a widely used antiarrhythmic agent with significant toxicities and drug interactions more likely to affect older adults. Nevertheless, data regarding amiodarone safety in this population are limited.
Methods: We conducted a retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from 2003 to 2024 .
Intravenous beta-blockers versus amiodarone on in-hospital mortality and safety profile in adult septic patients.
Med Intensiva (Engl Ed)
January 2025
Emergency Intensive Care Unit, Department of Emergency Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan Er Road, Guangzhou 510080, Guangdong, China; Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, Guangdong, China. Electronic address:
Objective: In the present study, we aimed to compare in-hospital mortality and safety of intravenous beta-blockers and amiodarone in septic patients with new-onset atrial fibrillation (NOAF). The null hypothesis is that there is no significant difference in in-hospital mortality and safety of Beta-blocker (BBs) and amiodarone in treating NOAF in patients with sepsis.
Design: We conducted a retrospective analysis based on the MIMIC-IV database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!